Tony Rianprakaisang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tony Rianprakaisang has a total of 811 co-authors. Here are the top co-authors by number of shared publications:
Robert G. Hendrickson
Oregon Health & Science University, Portland, OR, USA
4 shared publications- Adam Blumenberg
Department of Emergency Medicine, Columbia University Vagelos College of Physicians and Surgeons
2 shared publications - Robert G. Hendrickson
Oregon Health & Science University, 3181 SW Sam Jackson Park Road, CSB 550, Portland, OR, 97239, US.
2 shared publications Roy Gerona
University of California San Francisco, San Francisco, CA, USA
2 shared publications- Stephen Thornton
Kansas Poison Center and Alaska Poison Control Line, Kansas City, KS, USA
2 shared publications Aaron B. Deutsch
Division of Medical Toxicology, Department of Emergency and Hospital Medicine, Jefferson Health - Lehigh Valley Region, Allentown, PA, USA
1 shared publication
Latest Publications
- 5 October 2026
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 64  (sup2) , 1-181
North American Congress of Clinical Toxicology (NACCT) 2026
Background: Bupropion is a common cause of drug-induced seizures, but evidence guiding prophylactic therapy is limited. No prospective head-to-head comparison of phenobarbital and benzodiazepines for symptomatic bupropion overdose has been reported. Methods: We performed a 6-month prospective observational cohort study of patients with symptomatic bupropion overdose. Patients were grouped by receipt of seizure prophylaxis versus no prophylaxis, with agent-specific exploratory analyses for phenobarbital and lorazepam. Baseline characteristics and clinical outcomes were summarized using descriptive statistics. Continuous variables were assessed for normality using Shapiro-Wilk testing and summarized as median and interquartile range (IQR) when non-normally distributed. Categorical outcomes were compared using two-tailed Fisher exact tests with statistical significance defined as p < 0.05. Exploratory logistic regression evaluated seizure odds by prophylaxis group with and without adjustment for initial heart rate. Results: Fifty-five patients were enrolled: 39 received prophylaxis and 16 who did not receive recommended prophylaxis and served as controls. The prophylaxis agents used were phenobarbital in 20 patients, lorazepam in 12, other benzodiazepines in 6, and combined phenobarbital plus lorazepam in 1. Initial heart rate was 114 bpm (IQR 97–133.5) in the prophylaxis group versus 109 bpm (IQR 103.5–117.8) in controls. Reported ingestion dose was 2.70 g (IQR 1.39–5.18) versus 1.80 g (IQR 0.98–7.13), respectively. Three patients had a documented seizure history and were in the prophylaxis group, none of which experienced a seizure. Overall seizure incidence was lower with prophylaxis but did not reach statistical significance (1/39 [2.6%] vs 3/16 [18.8%]; p = 0.069). Proconvulsant co-ingestions were similar between groups (12/39 [30.8%] vs 7/16 [43.8%]; p = 0.370). Among patients with known ingestion ≥3 g, seizures occurred in 0/10 phenobarbital-treated patients, 1/4 lorazepam-treated patients, and 3/5 controls; phenobarbital differed from control (p = 0.022), whereas lorazepam did not (p = 0.524), and phenobarbital did not differ significantly from lorazepam (p = 0.286). Among patients with initial heart rate ≥120 bpm, seizures occurred in 0/7 phenobarbital-treated patients, 1/6 lorazepam-treated patients, and 3/4 controls; phenobarbital differed from control (p = 0.024), whereas lorazepam did not (p = 0.190) and phenobarbital did not differ significantly from lorazepam (p = 0.462). Exploratory logistic regression adjusted for initial heart rate found higher seizure odds in controls than in prophylaxis patients (OR 26.86, 95% CI 1.21–598.08; p = 0.038); initial heart rate showed a nonsignificant trend (OR 1.08 per bpm; p = 0.070). Conclusions: In this interim cohort, phenobarbital was associated with fewer seizures than no prophylaxis in higher-risk subgroups. However, direct phenobarbital-lorazepam comparisons were not statistically different. Findings remain hypothesis-generating given the small sample, observational design, statistical fragility, sparse seizure events, wide regression confidence intervals, and potential reporting bias. Background: Bromadiolone is a long-acting anticoagulant rodenticide that can cause severe and prolonged coagulopathy in humans, while clinical data from low- and middle-income countries remain limited. This study aimed to describe the clinical characteristics, laboratory findings, management strategies, and outcomes of patients with bromadiolone poisoning treated at an emergency center in Vietnam, and to identify factors associated with severe outcomes. We conducted a retrospective observational study of adult patients with confirmed bromadiolone poisoning admitted to the Emergency Center of Thai Nguyen Medical University Hospital, Vietnam, between February 2021 and August 2024. Demographic data, exposure characteristics, clinical manifestations, laboratory parameters, treatment details, and outcomes were extracted from medical records. Severe outcome was defined as major bleeding, international normalized ratio (INR) ≥ 5, requirement for blood product transfusion, or death. A total of 33 patients were included, with a median age of 46 years; 60.6% were male, and suicidal ingestion accounted for 66.7% of cases. Severe outcomes occurred in 7 patients (21.2%). Patients with severe outcomes presented significantly later after exposure (median 48 vs. 5.5 h, p = 0.001) and had markedly higher admission INR values. Bleeding manifestations and blood product transfusion were observed exclusively in the severe outcome group, and no in-hospital deaths occurred. In conclusion, bromadiolone poisoning is associated with substantial morbidity due to prolonged coagulopathy. Delayed hospital presentation and severe coagulopathy at admission are strongly associated with adverse outcomes, highlighting the importance of early recognition and appropriate vitamin K therapy in resource-limited settings. Methods: This retrospective observational study was conducted at the Emergency Center of Thai Nguyen Medical University Hospital, Thai Nguyen, Vietnam. Study population: All consecutive adult patients diagnosed with bromadiolone poisoning and admitted between February 2021 and August 2024 were eligible. Inclusion criteria: Exclusion criteria: Data collection Data extracted from medical records included: Results: Baseline characteristics: Thirty-three patients with bromadiolone poisoning were included. The median age was 46 years (IQR 27), and 20 patients (60.6%) were male. Suicidal ingestion was the most common exposure intent, accounting for 22 cases (66.7%). The median time from exposure to hospital presentation was 7 h (IQR 20), and the median estimated ingestion dose was 1 mg (IQR 4). Conclusions: Bromadiolone poisoning is a serious clinical condition associated with prolonged coagulopathy and a substantial risk of severe bleeding. Delayed hospital presentation and severe coagulopathy at admission are strongly associated with adverse outcomes. Early diagnosis, close monitoring of coagulation parameters, and appropriate vitamin K therapy are essential to improve outcomes, particularly in low- and middle-income countries. Background: Amiodarone is an antiarrhythmic drug used to treat life-threatening cardiac dysrhythmias, but its use is limited by multiorgan toxicity. Large-scale age-stratified data on clinical outcomes remain limited. The National Poison Data System (NPDS) is a national database of over 81 million de-identified case records from all 53 U.S. poison centers. The objective of this study was to describe amiodarone exposures reported to U.S. poison centers.
- 5 October 2026
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 64  (sup2) , 1-181
North American Congress of Clinical Toxicology (NACCT) 2026
Background: Bupropion is a common cause of drug-induced seizures, but evidence guiding prophylactic therapy is limited. No prospective head-to-head comparison of phenobarbital and benzodiazepines for symptomatic bupropion overdose has been reported. Methods: We performed a 6-month prospective observational cohort study of patients with symptomatic bupropion overdose. Patients were grouped by receipt of seizure prophylaxis versus no prophylaxis, with agent-specific exploratory analyses for phenobarbital and lorazepam. Baseline characteristics and clinical outcomes were summarized using descriptive statistics. Continuous variables were assessed for normality using Shapiro-Wilk testing and summarized as median and interquartile range (IQR) when non-normally distributed. Categorical outcomes were compared using two-tailed Fisher exact tests with statistical significance defined as p < 0.05. Exploratory logistic regression evaluated seizure odds by prophylaxis group with and without adjustment for initial heart rate. Results: Fifty-five patients were enrolled: 39 received prophylaxis and 16 who did not receive recommended prophylaxis and served as controls. The prophylaxis agents used were phenobarbital in 20 patients, lorazepam in 12, other benzodiazepines in 6, and combined phenobarbital plus lorazepam in 1. Initial heart rate was 114 bpm (IQR 97–133.5) in the prophylaxis group versus 109 bpm (IQR 103.5–117.8) in controls. Reported ingestion dose was 2.70 g (IQR 1.39–5.18) versus 1.80 g (IQR 0.98–7.13), respectively. Three patients had a documented seizure history and were in the prophylaxis group, none of which experienced a seizure. Overall seizure incidence was lower with prophylaxis but did not reach statistical significance (1/39 [2.6%] vs 3/16 [18.8%]; p = 0.069). Proconvulsant co-ingestions were similar between groups (12/39 [30.8%] vs 7/16 [43.8%]; p = 0.370). Among patients with known ingestion ≥3 g, seizures occurred in 0/10 phenobarbital-treated patients, 1/4 lorazepam-treated patients, and 3/5 controls; phenobarbital differed from control (p = 0.022), whereas lorazepam did not (p = 0.524), and phenobarbital did not differ significantly from lorazepam (p = 0.286). Among patients with initial heart rate ≥120 bpm, seizures occurred in 0/7 phenobarbital-treated patients, 1/6 lorazepam-treated patients, and 3/4 controls; phenobarbital differed from control (p = 0.024), whereas lorazepam did not (p = 0.190) and phenobarbital did not differ significantly from lorazepam (p = 0.462). Exploratory logistic regression adjusted for initial heart rate found higher seizure odds in controls than in prophylaxis patients (OR 26.86, 95% CI 1.21–598.08; p = 0.038); initial heart rate showed a nonsignificant trend (OR 1.08 per bpm; p = 0.070). Conclusions: In this interim cohort, phenobarbital was associated with fewer seizures than no prophylaxis in higher-risk subgroups. However, direct phenobarbital-lorazepam comparisons were not statistically different. Findings remain hypothesis-generating given the small sample, observational design, statistical fragility, sparse seizure events, wide regression confidence intervals, and potential reporting bias. Background: Bromadiolone is a long-acting anticoagulant rodenticide that can cause severe and prolonged coagulopathy in humans, while clinical data from low- and middle-income countries remain limited. This study aimed to describe the clinical characteristics, laboratory findings, management strategies, and outcomes of patients with bromadiolone poisoning treated at an emergency center in Vietnam, and to identify factors associated with severe outcomes. We conducted a retrospective observational study of adult patients with confirmed bromadiolone poisoning admitted to the Emergency Center of Thai Nguyen Medical University Hospital, Vietnam, between February 2021 and August 2024. Demographic data, exposure characteristics, clinical manifestations, laboratory parameters, treatment details, and outcomes were extracted from medical records. Severe outcome was defined as major bleeding, international normalized ratio (INR) ≥ 5, requirement for blood product transfusion, or death. A total of 33 patients were included, with a median age of 46 years; 60.6% were male, and suicidal ingestion accounted for 66.7% of cases. Severe outcomes occurred in 7 patients (21.2%). Patients with severe outcomes presented significantly later after exposure (median 48 vs. 5.5 h, p = 0.001) and had markedly higher admission INR values. Bleeding manifestations and blood product transfusion were observed exclusively in the severe outcome group, and no in-hospital deaths occurred. In conclusion, bromadiolone poisoning is associated with substantial morbidity due to prolonged coagulopathy. Delayed hospital presentation and severe coagulopathy at admission are strongly associated with adverse outcomes, highlighting the importance of early recognition and appropriate vitamin K therapy in resource-limited settings. Methods: This retrospective observational study was conducted at the Emergency Center of Thai Nguyen Medical University Hospital, Thai Nguyen, Vietnam. Study population: All consecutive adult patients diagnosed with bromadiolone poisoning and admitted between February 2021 and August 2024 were eligible. Inclusion criteria: Exclusion criteria: Data collection Data extracted from medical records included: Results: Baseline characteristics: Thirty-three patients with bromadiolone poisoning were included. The median age was 46 years (IQR 27), and 20 patients (60.6%) were male. Suicidal ingestion was the most common exposure intent, accounting for 22 cases (66.7%). The median time from exposure to hospital presentation was 7 h (IQR 20), and the median estimated ingestion dose was 1 mg (IQR 4). Conclusions: Bromadiolone poisoning is a serious clinical condition associated with prolonged coagulopathy and a substantial risk of severe bleeding. Delayed hospital presentation and severe coagulopathy at admission are strongly associated with adverse outcomes. Early diagnosis, close monitoring of coagulation parameters, and appropriate vitamin K therapy are essential to improve outcomes, particularly in low- and middle-income countries. Background: Amiodarone is an antiarrhythmic drug used to treat life-threatening cardiac dysrhythmias, but its use is limited by multiorgan toxicity. Large-scale age-stratified data on clinical outcomes remain limited. The National Poison Data System (NPDS) is a national database of over 81 million de-identified case records from all 53 U.S. poison centers. The objective of this study was to describe amiodarone exposures reported to U.S. poison centers.
- Open Access
- 13 September 2024
- Published by Taylor & Francis in Toxicology Communications
- Vol. 8  (1)
A pediatric case of generalized tetanus treated with intrathecal baclofen
- 13 September 2024
- Published by Taylor & Francis in Toxicology Communications
- Vol. 8  (1)
Open AccessA pediatric case of generalized tetanus treated with intrathecal baclofen
- 3 July 2023
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 61  (7) , 561-562
Plasma concentrations of phenibut and mitragynine in a single patient
- 3 July 2023
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 61  (7) , 561-562
Plasma concentrations of phenibut and mitragynine in a single patient
- 27 October 2021
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 60  (4) , 543-544
Prolonged coagulopathy following repeated diphacinone ingestion
Dear Editor, Diphacinone (2-Diphenylacetyl-1,3-Indandione) is an inandione vitamin-K antagonist. Like coumarins, diphacinone inhibits the enzyme vitamin K epoxide reductase resulting in a deficienc...
- 27 October 2021
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 60  (4) , 543-544
Prolonged coagulopathy following repeated diphacinone ingestion
Dear Editor, Diphacinone (2-Diphenylacetyl-1,3-Indandione) is an inandione vitamin-K antagonist. Like coumarins, diphacinone inhibits the enzyme vitamin K epoxide reductase resulting in a deficienc...
- 21 April 2021
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 59  (12) , 1234-1238
Factors associated with seizure development after bupropion overdose: a review of the toxicology investigators consortium
Bupropion is an aminoketone antidepressant. A major concern in bupropion toxicity is seizure activity, which can occur up to 24 h from ingestion. It is difficult to predict which patients will have...
- 21 April 2021
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 59  (12) , 1234-1238
Factors associated with seizure development after bupropion overdose: a review of the toxicology investigators consortium
Bupropion is an aminoketone antidepressant. A major concern in bupropion toxicity is seizure activity, which can occur up to 24 h from ingestion. It is difficult to predict which patients will have...
- 4 November 2019
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 58  (7) , 785-786
Acetaminophen-associated methemoglobinemia
(2019). Acetaminophen-associated methemoglobinemia. Clinical Toxicology. Ahead of Print.
- 4 November 2019
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 58  (7) , 785-786
Acetaminophen-associated methemoglobinemia
(2019). Acetaminophen-associated methemoglobinemia. Clinical Toxicology. Ahead of Print.
- 26 August 2019
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 58  (6) , 495-497
Methemoglobinemia associated with massive acetaminophen ingestion: a case series
Background: Acetaminophen is a common pharmaceutical ingestion reported to US poison centers. In overdose, toxic metabolites are known to cause hepato- and nephrotoxicity. While G6PD deficiency may be a risk factor for methemoglobin production in the setting of acetaminophen overdose, it is rarely reported in patients who do not have this condition. Methods: We present two cases of methemoglobinemia following massive acetaminophen ingestion with no known history of G6PD deficiency or other substances known to induce methemoglobinemia. The two cases had peak methemoglobin measurements of 32% and 12% respectively, and both were treated with methylene blue. Discussion: A number of mechanisms may be involved in production of methemoglobin in the setting of massive acetaminophen ingestion including NAPQI-induced oxidation, depletion of glutathione stores, and production of oxidant-metabolites including paraaminophenol. While it is unlikely that the majority of acetaminophen overdoses result in any clinically significant methemoglobinemia, massive acetaminophen overdose may be complicated by development of methemoglobinemia. Conclusion: Physicians should be aware of the possibility that massive acetaminophen ingestion may be complicated by methemoglobinemia in rare instances. Further studies should aim to characterize the metabolic pathways leading to possible methemoglobinemia in humans after large acetaminophen ingestions.
- 26 August 2019
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 58  (6) , 495-497
Methemoglobinemia associated with massive acetaminophen ingestion: a case series
Background: Acetaminophen is a common pharmaceutical ingestion reported to US poison centers. In overdose, toxic metabolites are known to cause hepato- and nephrotoxicity. While G6PD deficiency may be a risk factor for methemoglobin production in the setting of acetaminophen overdose, it is rarely reported in patients who do not have this condition. Methods: We present two cases of methemoglobinemia following massive acetaminophen ingestion with no known history of G6PD deficiency or other substances known to induce methemoglobinemia. The two cases had peak methemoglobin measurements of 32% and 12% respectively, and both were treated with methylene blue. Discussion: A number of mechanisms may be involved in production of methemoglobin in the setting of massive acetaminophen ingestion including NAPQI-induced oxidation, depletion of glutathione stores, and production of oxidant-metabolites including paraaminophenol. While it is unlikely that the majority of acetaminophen overdoses result in any clinically significant methemoglobinemia, massive acetaminophen overdose may be complicated by development of methemoglobinemia. Conclusion: Physicians should be aware of the possibility that massive acetaminophen ingestion may be complicated by methemoglobinemia in rare instances. Further studies should aim to characterize the metabolic pathways leading to possible methemoglobinemia in humans after large acetaminophen ingestions.
- 24 May 2019
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 58  (3) , 215-216
Commercial cannabidiol oil contaminated with the synthetic cannabinoid AB-FUBINACA given to a pediatric patient
(2019). Commercial cannabidiol oil contaminated with the synthetic cannabinoid AB-FUBINACA given to a pediatric patient. Clinical Toxicology. Ahead of Print.
- 24 May 2019
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 58  (3) , 215-216
Commercial cannabidiol oil contaminated with the synthetic cannabinoid AB-FUBINACA given to a pediatric patient
(2019). Commercial cannabidiol oil contaminated with the synthetic cannabinoid AB-FUBINACA given to a pediatric patient. Clinical Toxicology. Ahead of Print.